• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases) - Product Image Special Offer Sale Banner

Autologous Stem Cell and Non-Stem Cell Based Therapies Market (2012-2017) (Neurodegenerative, cardiovascular, cancer & autoimmune, skin and infectious diseases)

  • Published: October 2012
  • 130 Pages
  • Markets and Markets
Special Offer Banner
25%
OFF
Offer ends 31st Aug 2014

FEATURED COMPANIES

  • Antria (Cro) (U.S.)
  • Cytori (U.S.)
  • Genesis Biopharma (U.S.)
  • Opexa Therapeutics (U.S.)
  • Regeneus (Australia)
  • Tengion (U.S.)
  • MORE

Autologous cell therapies are new therapeutic intervention where it introduces or uses cells or tissues from the individual, cultured, expanded and re-introduced at the site of the disease of the donor. They are widely promoted as next pillar or advancement in medical care.

Growth of the market is very rapid especially in regulatory approvals, applications areas and rapid improvements in efficacy of treatment; it has enormous advantages over allogenic stem cell therapies. Autologous transplants are relatively safe procedures, with less rates of complications and infections compared with allogenic transplants. In many instances, much of the procedure can be done on an outpatient basis. It helps in treating various dreadful diseases by transplanting their own body cells where it results in meager chances of transplant rejection.

We have also profiled leading players of this industry with their recent developments and other strategic industry activities. These include: Neostem (U.S.), Tengion (U.S.), Brainstorm Cell Therapeutics (U.S.), Dendreon Corporation (U.S.), Georgia Health Sciences University (U.S.), Regenexx (U.S.), Regeneus (Australia), Cytori Therapeutics (U.S.), READ MORE >

1 Introduction

1.1 Key Take Aways

1.2 Report Scope

1.3 Research Methodology

1.4 Key Data Sources



2 Executive Summary



3 Autologous Cell Therapy (Act)-Technology Landscape Analysis

3.1 Autologous Cell Therapy Technology

3.1.1 Technology Overview

3.1.2 Technology Process

3.1.3 Application Areas

3.1.3.1 Neurodegenerative Diseases

3.1.3.2 Cardiovascular Diseases

3.1.3.3 Cancer And Autoimmune Diseases

3.1.3.4 Skin Transplantation

3.1.3.5 Infectious Diesease

3.2 Technology Trend Analysis

3.3 Value Chain Analysis



4 Technology Investment Potential

4.1 Investment Climate Assessment

4.1.1 Investor Networks

4.1.1.1 Public Funding Bodies

4.1.1.2 Funding/Grants From Ngo Organizations

4.1.1.3 Private Investors And Venture Capital Firms

4.1.1.4 Insights On Current And Future Tech-Investment Trends

4.1.1.5 Investor Inclination And Patterns

4.2 Investment Oppurtunities

4.2.1 Licensing And Acquisition

4.2.2 Analysis Of Potential Application Areas For Technology Investment



5 Market Landscape Analysis

5.1 Autologous Vs Allogenic – Market Landscape

5.2 Global Market Forecast

5.3 Market Dynamics

5.3.1 Drivers

5.3.2 Restraints

5.3.3 Challenges

5.3.4 Demand Side Analysis



6 Act – Technology Adoption Potential And Development By Geography

6.1 Introduction

6.2 Us, Canada, Latin America

6.3 Uk, Germany, France

6.4 Australia, Korea, Japan, Row

6.5 Regions With High Technology Adoption



7 Competitive Landscape

7.1 Mergers And Acquisitions

7.2 Partnerships And Collaborations

7.3 New Product Development Initiatives (Those In Pipeline)



8 Patent Analysis



9 Technology Analysis And Road Mapping

9.1 Introduction

9.2 Clinical Trials Details – Medical Centers And Universities

9.3 Data Pertaining To Cell Therapy Clinical Trials



10 Analyst Insights And Recommendations

11 Company Profiles

11.1 Antria (Cro) (U.S.)

11.2 Bioheart (U.S.)

11.3 Brainstorm Cell Therapeutics (U.S.)

11.4 Cytori (U.S.)

11.5 Dendreon Corporation (U.S.)

11.6 Fibrocell (U.S.)

11.7 Genesis Biopharma (U.S.)

11.8 Georgia Health Sciences University (U.S.)

11.9 Neostem (U.S.)

11.1 Opexa Therapeutics (U.S.)

11.11 Orgenesis (U.S.)

11.12 Regenexx (U.S.)

11.13 Regeneus (Australia)

11.14 Tengion (U.S.)

11.15 Tigenix (Belgium)

11.16 Virxsys (U.S.)



12 Appendix



13 Glossary

List Of Tables



Table 1 Funding Details In Europe
Table 2 Licensing & Acquisition
Table 3 Data Pertaining To Diseases - Disease Incidence & Treatment Costs
Table 4 Drivers
Table 5 Restraints
Table 6 U.S. Fda Guidance Documents
Table 7 Mergers & Acquisitions
Table 8 Partnerships & Collaborations
Table 9 New Product Development Initiatives (Those In-Pipeline)
Table 10 Clinical Trials Details – Medical Centers & Universities
Table 11 Key Patents
Table 12 New Product Development Initiatives (In-Pipeline)

List Of Figures

Fig 1 Act Market Revenue Forecast
Fig 2 Segmentation Of Cell Therapy
Fig 3 Act Market Revenue Forecast
Fig 4 Percentage Of Shareholders In The Autologous Cell Therapy
Fig 5 Investor Networks
Fig 6 Nih Funding In Usa For Autologous Cell Therapies In 2010
Fig 7 Opportunity Strategic Evaluation Analysis
Fig 8 Market Revenue Of Autologous Vs Allogenic Cell Therapy Products (2011)
Fig 9 Market Share Of Autologous Vs Allogenic Cell Therapy Products (2011)
Fig 10 Segmentation Of Cell Therapy Treatment
Fig 11 Segmentation By Application Areas
Fig 12 Autologous Cell Therapy Market Revenue Forecast, 2012 - 2017 ($Million)
Fig 13 Market Share (%) And Revenues ($Millions) By Region (2012)
Fig 14 Market Share (%) And Revenues ($Millions) By Region (2017)
Fig 15 Market Share (%) And Revenues ($Millions) By Applications (2012)
Fig 16 Market Share (%) And Revenues ($Millions) By Applications (2017)
Fig 17 Number Of M&A's In Act Technology
Fig 18 Geographical Autologous Technologies/ Product-Patent Distribution
Fig 19 Regional Data Of Clinical Trials Of The Technology
Fig 20 Clinical Trials By Indication
Fig 21 Stem Cell Types Employed In Interventional Clinical Trials
Fig 22 Source Of Mesenchymal Stem Cells (Mscs)
Fig 23 Ongoing Clinical Trials
Fig 24 Number Of Cell Therapy Clinical Trials By Region
Fig 25 Number Of Cell Therapy Clinical Trials By Country
Fig 26 Number Of Pubmed Publications
Fig 27 Country Wise Publication Details

- Antria (Cro) (U.S.)
- Bioheart (U.S.)
- Brainstorm Cell Therapeutics (U.S.)
- Cytori (U.S.)
- Dendreon Corporation (U.S.)
- Fibrocell (U.S.)
- Genesis Biopharma (U.S.)
- Georgia Health Sciences University (U.S.)
- Neostem (U.S.)
- Opexa Therapeutics (U.S.)
- Orgenesis (U.S.)
- Regenexx (U.S.)
- Regeneus (Australia)
- Tengion (U.S.)
- Tigenix (Belgium)
- Virxsys (U.S.)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos